FDA Approves Legend Biotech's CARVYKTI for Multiple Myeloma
Ticker: LEGN · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: fda-approval, drug-approval, oncology, multiple-myeloma
TL;DR
FDA greenlights Legend Biotech's CARVYKTI for late-stage multiple myeloma patients.
AI Summary
On April 5, 2024, Legend Biotech Corporation announced that the U.S. FDA approved CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed antibody. This approval marks a significant milestone for the company and patients.
Why It Matters
The FDA approval of CARVYKTI provides a new, potentially life-extending treatment option for patients with relapsed or refractory multiple myeloma who have exhausted other therapies.
Risk Assessment
Risk Level: low — This filing is an announcement of a regulatory approval, which is generally positive news and does not introduce new risks.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI (drug) — FDA Approved Treatment
- ciltacabtagene autoleucel (drug) — Active Ingredient of CARVYKTI
- U.S. FDA (company) — Regulatory Body
- April 5, 2024 (date) — Date of Report
FAQ
What is the specific indication for CARVYKTI's FDA approval?
The U.S. FDA approved CARVYKTI for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed antibody.
What is the active ingredient in CARVYKTI?
The active ingredient in CARVYKTI is ciltacabtagene autoleucel.
What type of cancer does CARVYKTI treat?
CARVYKTI treats multiple myeloma.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 8, 2024, reporting information as of April 5, 2024.
What is Legend Biotech Corporation's principal executive office address?
Legend Biotech Corporation's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-04-08 07:03:22
Filing Documents
- form6-kxfdaapproval6xk.htm (6-K) — 19KB
- legendbiotech_carvyktifdaa.htm (EX-99.1) — 90KB
- image_0.jpg (GRAPHIC) — 8KB
- 0001801198-24-000028.txt ( ) — 122KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date April 5, 2024 By s Ying Huang Name Ying Huang, Ph.D. Title Chief Executive Officer